Chitra Choudhary, MD
Endocrinology, Diabetes & Metabolism · Dover, DENPI 1467749374
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (39.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Amgen accounts for 83.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $2,701 and has fallen 94.2% since, to $156 in 2025.
Across 50 payments — averaging $95.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Xeris Pharmaceuticals, Inc.$150
- Novo Nordisk$118
- Lilly USA, LLC$77
- Sanofi-aventis U.S. LLC$76
- AstraZeneca$59
- plus $322 from 12 others
Across 3 payments — averaging $8667.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$26K
What the payments were for
- Speaking & faculty fees$1,45530%
- Travel & lodging$1,91140%
- Food & beverage$1,41530%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 14 | $3,991 |
| Xeris Pharmaceuticals, Inc. | 3 | $150 |
| Novo Nordisk | 6 | $118 |
| Lilly USA, LLC | 3 | $77 |
| Sanofi-aventis U.S. LLC | 5 | $76 |
| AstraZeneca | 3 | $59 |
| Boehringer Ingelheim | 2 | $45 |
| Abbott | 2 | $39 |
| Insulet Corporation | 1 | $36 |
| Johnson & Johnson | 2 | $34 |
| Medtronic | 2 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| BD | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Chiesi USA, Inc. | 1 | $16 |
| BETA Bionics, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,793 in reported general payments places this provider in the 80th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
See all endocrinology, diabetes & metabolism providers in Delaware →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 213 | $293,053 |
| MounjaroTirzepatide | 204 | $228,425 |
| RecorlevLevoketoconazole | 12 | $224,777 |
| JardianceEmpagliflozin | 59 | $80,534 |
| TymlosAbaloparatide | 15 | $37,104 |
| FarxigaDapagliflozin Propanediol | 23 | $32,613 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 35 | $29,456 |
| TrulicityDulaglutide | 18 | $18,419 |
| Novolog FlexpenInsulin Aspart | 42 | $10,862 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $9,157 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $6,730 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 22 | $5,831 |
| Testosterone | 44 | $5,379 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 36 | $5,212 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $118 | $293,053213 claims |
| Lilly USA, LLCMounjaro, Trulicity | $77 | $246,844222 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $150 | $224,77712 claims |
| Boehringer IngelheimJardiance | $45 | $80,53459 claims |
| AstraZenecaFarxiga | $59 | $32,61323 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $3,453395 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
Other endocrinology, diabetes & metabolism in Dover
- Manveen DuggalDover$2K
- Wai Wai LinDover$762
- Hira ShakeelDover$240
- Hajira AmirDover$187
- Hasitha VemulaDover$96
- Ripudaman HundalNewark$370K
- Nira MadisiMilford$23K
- Francisco PadillaSeaford$22K
- Reetu SinghLewes$9K
- Joanna KhatibMillsboro$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.